Learn how secondary hyperparathyroidism (SHPT) is diagnosed, monitored and managed, and what you can do to improve its management
diagnosed and monitored?
Secondary hyperparathyroidism is diagnosed through a blood test.1 Regular blood tests are also required to monitor parathyroid hormone, vitamin D, calcium and phosphate levels.1
The regularity of the blood tests will depend on how advanced your chronic kidney disease is, with more advanced cases requiring more frequent monitoring.1
The blood tests will inform your nephrologist of how well your treatment is going, allowing them to adjust your treatment plan if necessary.
Effective management is possible, especially if it is diagnosed and treated early in the course of chronic kidney disease.2,3
The goal of treatment is to control your parathyroid hormone level by restoring the balance of your vitamin D hormone, calcium and phosphate levels.4
To achieve this goal, your nephrologist may prescribe different types of medication, either alone or in combination.4
Medications that increase the level of vitamin D hormone5–8
Nutritional vitamin D (cholecalciferol and ergocalciferol)
Available over the counter / prescription5,6
Vitamin D prohormone (calcifediol)
Sometimes available on prescription7
Vitamin D hormone (calcitriol)
Available on prescription8
Medications that reduce the level of phosphate9
Available on prescription9
Attend your check-ups as scheduled so that your nephrologist can monitor your parathyroid hormone, calcium, phosphate and vitamin D levels carefully.
Always take your medications as instructed by your nephrologist.
To remember when to take your medications, make a note on your calendar, set an alarm on your phone and/or ask your caregiver to remind you.
By taking these measures, you can improve the
management of your secondary hyperparathyroidism and
potentially reduce the risk of complications.
If you can’t keep up with your treatment plan for any
reason, please tell your nephrologist or nurse.
- Kidney Disease: Improving Global Outcomes (KDIGO) Work Group. Kidney Int Suppl. 2017;7:1–59.
- Tomasello S. Diabetes Spectr. 2008;21:19–25.
- Locatelli F et al. Nephrol Dial Transplant. 2002;17:723–31.
- Cunningham J et al. Clin J Am Soc Nephrol. 2011;6:913–21.
- RPH Pharmaceuticals AB. Ergocalciferol Injection BP 300,000 IU Summary of Product Characteristics; 2019 December 6.
- Colonis Pharma Ltd. Colecalciferol 1,000 IU Capsules Summary of Product Characteristics; 2020 February 20.
- Desma Pharma. Dedrogyl 15 mg/100 mL Solution Buvable en Gouttes Résumé des Caractéristiques du Produit; 2021 March 30.
- Atnahs Pharma UK Ltd. Rocaltrol 0.5 microgram Capsules Summary of Product Characteristics; 2020 December 23.
- Shire Pharmaceuticals Limited. Fosrenol 500 mg Chewable Tablets Summary of Product Characteristics; 2017 September 6.